tetano
Editor, Senior Moderator
Porto Biomed J
. 2021 Apr 13;6(2):e134.
doi: 10.1097/j.pbj.0000000000000134. eCollection Mar-Apr 2021.
Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial
Margarida Tavares[SUP] 1 2 3 [/SUP], Mariana Farraia[SUP] 1 4 [/SUP], Susana Silva[SUP] 2 3 [/SUP], Ana Margarida Ribeiro[SUP] 5 [/SUP], Milton Severo[SUP] 1 6 [/SUP], In?s Paci?ncia[SUP] 1 4 [/SUP], Raquel Ribeiro[SUP] 5 [/SUP], Venceslau Hespanhol[SUP] 3 5 [/SUP], Tiago Guimar?es[SUP] 5 [/SUP], Jorge Almeida[SUP] 5 [/SUP], Fernando Magro[SUP] 3 5 [/SUP], Ant?nio Sarmento[SUP] 2 3 [/SUP], Ana Marta Oliveira[SUP] 5 [/SUP], Andr? Moreira[SUP] 1 4 7 [/SUP]
Affiliations
Abstract
Background: Montelukast, a safe drug widely use in asthmatic patients, may be an adjuvant in the treatment of Covid-19, either by improving lung injury and inflammation, or by acting as an anti-viral drug. We aim to assess the efficacy and safety of montelukast as add-on treatment in patients with Covid-19.
Methods: We propose a randomized, controlled, parallel, open-label trial involving 160 hospitalized adult patients with confirmed Covid-19. Patients will be randomly assigned in a 1:1 ratio to receive either montelukast 10 mg, once a day for 14 days, in addition to standard of care (SoC), or SoC alone. SoC will follow the best practice for treating these patients, according to updated recommendations. The primary outcome is time to recovery. Participants will be assessed using diary cards to capture data on treatment-related improvements in an 8-point ordinal scale. Secondary endpoints will include changes in respiratory and inflammatory parameters, and adverse events. This phase IV clinical trial will take place at the University Hospital of S?o Jo?o, Porto. EudraCT number: 2020-001747-21.
Results: This study intends to generate scientific evidence on efficacy and safety of montelukast as add-on treatment in Covid-19. The results will be essential to improve clinical outcomes which remains to be determined.
Conclusion: Montelukast has been suggested as a potential drug with 2 main actions on Covid-19. The validation of montelukast as an adjuvant treatment may improve lung injury, inflammation, and symptoms leading to a better prognosis. The use of this drug may fulfil the existing gap on therapeutic options.
Keywords: Covid-19; SARS-CoV-2; coronavirus; montelukast; randomized controlled trial; treatment.
. 2021 Apr 13;6(2):e134.
doi: 10.1097/j.pbj.0000000000000134. eCollection Mar-Apr 2021.
Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial
Margarida Tavares[SUP] 1 2 3 [/SUP], Mariana Farraia[SUP] 1 4 [/SUP], Susana Silva[SUP] 2 3 [/SUP], Ana Margarida Ribeiro[SUP] 5 [/SUP], Milton Severo[SUP] 1 6 [/SUP], In?s Paci?ncia[SUP] 1 4 [/SUP], Raquel Ribeiro[SUP] 5 [/SUP], Venceslau Hespanhol[SUP] 3 5 [/SUP], Tiago Guimar?es[SUP] 5 [/SUP], Jorge Almeida[SUP] 5 [/SUP], Fernando Magro[SUP] 3 5 [/SUP], Ant?nio Sarmento[SUP] 2 3 [/SUP], Ana Marta Oliveira[SUP] 5 [/SUP], Andr? Moreira[SUP] 1 4 7 [/SUP]
Affiliations
- PMID: 33869886
- PMCID: PMC8049153
- DOI: 10.1097/j.pbj.0000000000000134
Abstract
Background: Montelukast, a safe drug widely use in asthmatic patients, may be an adjuvant in the treatment of Covid-19, either by improving lung injury and inflammation, or by acting as an anti-viral drug. We aim to assess the efficacy and safety of montelukast as add-on treatment in patients with Covid-19.
Methods: We propose a randomized, controlled, parallel, open-label trial involving 160 hospitalized adult patients with confirmed Covid-19. Patients will be randomly assigned in a 1:1 ratio to receive either montelukast 10 mg, once a day for 14 days, in addition to standard of care (SoC), or SoC alone. SoC will follow the best practice for treating these patients, according to updated recommendations. The primary outcome is time to recovery. Participants will be assessed using diary cards to capture data on treatment-related improvements in an 8-point ordinal scale. Secondary endpoints will include changes in respiratory and inflammatory parameters, and adverse events. This phase IV clinical trial will take place at the University Hospital of S?o Jo?o, Porto. EudraCT number: 2020-001747-21.
Results: This study intends to generate scientific evidence on efficacy and safety of montelukast as add-on treatment in Covid-19. The results will be essential to improve clinical outcomes which remains to be determined.
Conclusion: Montelukast has been suggested as a potential drug with 2 main actions on Covid-19. The validation of montelukast as an adjuvant treatment may improve lung injury, inflammation, and symptoms leading to a better prognosis. The use of this drug may fulfil the existing gap on therapeutic options.
Keywords: Covid-19; SARS-CoV-2; coronavirus; montelukast; randomized controlled trial; treatment.